BRAF and melanoma: A phase III double-blind placebo controlled randomized trial of dabrafenib with trametinib, an MEK inhibitor, was carried out for adjuvant therapy for patients with high chances of BRAF V600 mutant-positive stage III melanoma after surgical resection (COMBI-AD).